{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T06:13:25Z","timestamp":1793427205188,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,6,2]],"date-time":"2027-06-02T00:00:00Z","timestamp":1811894400000},"content-version":"am","delay-in-days":336,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.contraception.2025.111209","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T06:51:32Z","timestamp":1757659892000},"page":"111209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Research gaps in evidence-based contraception guidance: US Medical Eligibility Criteria for Contraceptive Use, 2024, and US Selected Practice Recommendations for Contraceptive Use, 2024"],"prefix":"10.1016","volume":"159","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2213-6382","authenticated-orcid":false,"given":"Naomi K.","family":"Tepper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren B.","family":"Zapata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura K.","family":"Whiteman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2025.111209_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7304a1","article-title":"US\u00a0Medical eligibility criteria for contraceptive use, 2024","volume":"73","author":"Nguyen","year":"2024","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.contraception.2025.111209_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7303a1","article-title":"US\u00a0Selected Practice Recommendations for Contraceptive Use, 2024","volume":"73","author":"Curtis","year":"2024","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.contraception.2025.111209_bib3","article-title":"Combined oral contraceptives: venous thrombosis","volume":"2014","author":"de Bastos","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2025.111209_bib4","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3389\/fneur.2019.00993","article-title":"Oral contraceptive use and increased risk of stroke: a dose-response meta-analysis of observational studies","volume":"10","author":"Li","year":"2019","journal-title":"Front Neurol"},{"key":"10.1016\/j.contraception.2025.111209_bib5","article-title":"Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke","volume":"2015","author":"Roach","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2025.111209_bib6","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.contraception.2016.10.005","article-title":"Nonoral combined hormonal contraceptives and thromboembolism: a systematic review","volume":"95","author":"Tepper","year":"2017","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.111209_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.contraception.2023.110310","article-title":"Comparison of estrogenic components used for hormonal contraception","volume":"130","author":"Stanczyk","year":"2024","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.111209_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1428597","article-title":"Are natural estrogens used in contraception at lower risk of venous thromboembolism than synthetic ones? A systematic literature review and meta-analysis","volume":"15","author":"Douxfils","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.contraception.2025.111209_bib9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/AOG.0000000000005509","article-title":"Venous thromboembolic risk of estradiol Valerate-Dienogest compared with ethinyl Estradiol-Levonorgestrel combined oral contraceptives","volume":"143","author":"Bauerfeind","year":"2024","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2025.111209_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.contraception.2024.110727","article-title":"Lower reporting of venous thromboembolisms events with natural estrogen-based combined oral contraceptives compared to ethinylestradiol-containing pills: a disproportionality analysis of the eudravigilance database","volume":"142","author":"Didembourg","year":"2025","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.111209_bib11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.contraception.2016.06.010","article-title":"Impact of estrogen type on cardiovascular safety of combined oral contraceptives","volume":"94","author":"Dinger","year":"2016","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.111209_bib12","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/13625187.2021.1987410","article-title":"Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5\u00a0mg) and 17\u00a0beta-oestradiol (1.5\u00a0mg) (PRO-E2 study): risk of venous and arterial thromboembolism","volume":"26","author":"Reed","year":"2021","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2025.111209_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.contraception.2025.110861","article-title":"Estetrol\/Drospirenone safety in a population with cardiovascular risk factors","author":"Creinin","year":"2025","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.111209_bib14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.contraception.2010.02.015","article-title":"Guidance on medical eligibility criteria for contraceptive use: identification of research gaps","volume":"82","author":"Folger","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.111209_bib15","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.contraception.2016.07.017","article-title":"Research gaps from evidence-based contraception guidance: the US medical eligibility criteria for contraceptive use, 2016, and the US Selected Practice Recommendations for Contraceptive Use, 2016","volume":"94","author":"Horton","year":"2016","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.111209_bib16","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/AOG.0000000000004896","article-title":"Association of progestogens and venous thromboembolism among women of reproductive age","volume":"140","author":"Cockrum","year":"2022","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2025.111209_bib17","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1177\/2047487318774847","article-title":"Association between progestin-only contraceptive use and cardiometabolic outcomes: a systematic review and meta-analysis","volume":"25","author":"Glisic","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.contraception.2025.111209_bib18","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.contraception.2016.04.014","article-title":"Progestin-only contraception and thromboembolism: a systematic review","volume":"94","author":"Tepper","year":"2016","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.111209_bib19","article-title":"Progestin-only contraception and thrombosis: an updated systematic review","author":"Tepper","year":"2025","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.111209_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2006.08.015","article-title":"Deep venous thrombosis and pulmonary embolism in hospitalized patients with sickle cell disease","volume":"119","author":"Stein","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.contraception.2025.111209_bib21","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.blre.2015.12.003","article-title":"Coagulation abnormalities of sickle cell disease: relationship with clinical outcomes and the effect of disease modifying therapies","volume":"30","author":"Noubouossie","year":"2016","journal-title":"Blood Rev"},{"key":"10.1016\/j.contraception.2025.111209_bib22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12959-018-0179-z","article-title":"Sickle cell disease, sickle trait and the risk for venous thromboembolism: a systematic review and meta-analysis","volume":"16","author":"Noubiap","year":"2018","journal-title":"Thromb J"},{"key":"10.1016\/j.contraception.2025.111209_bib23","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1182\/blood-2009-05-220921","article-title":"Sickle cell disease and stroke","volume":"114","author":"Verduzco","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.contraception.2025.111209_bib24","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1111\/jth.12744","article-title":"Venous thromboembolism incidence in the cooperative study of sickle cell disease","volume":"12","author":"Naik","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.contraception.2025.111209_bib25","doi-asserted-by":"crossref","unstructured":"Nguyen AT, Nandi P, Roe AH, Pecker L, Naik R, Whiteman MK, et al. Safety of hormonal contraception among women with sickle cell disease: an updated systematic review. Contraception. (2025).","DOI":"10.1016\/j.contraception.2025.111275"},{"key":"10.1016\/j.contraception.2025.111209_bib26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1681\/ASN.2007030308","article-title":"Chronic kidney disease increases risk for venous thromboembolism","volume":"19","author":"Wattanakit","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.contraception.2025.111209_bib27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11239-016-1437-1","article-title":"Venous thromboembolism in chronic kidney disease: epidemiology, the role of proteinuria, CKD severity and therapeutics","volume":"43","author":"Dobrowolski","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.contraception.2025.111209_bib28","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/916760","article-title":"Primary nephrotic syndrome in adults as a risk factor for pulmonary embolism: an Up-to-Date review of the literature","volume":"2014","author":"Mirrakhimov","year":"2014","journal-title":"Int J Nephrol"},{"key":"10.1016\/j.contraception.2025.111209_bib29","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.thromres.2005.03.030","article-title":"Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management","volume":"118","author":"Singhal","year":"2006","journal-title":"Thromb Res"},{"key":"10.1016\/j.contraception.2025.111209_bib30","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/ndt\/gfx212","article-title":"Risk and complications of venous thromboembolism in dialysis patients","volume":"33","author":"Molnar","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.contraception.2025.111209_bib31","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1161\/CIRCULATIONAHA.107.716951","article-title":"High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study","volume":"117","author":"Mahmoodi","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.contraception.2025.111209_bib32","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.amjmed.2007.08.042","article-title":"Venous thromboembolism in patients hospitalized with nephrotic syndrome","volume":"121","author":"Kayali","year":"2008","journal-title":"Am J Med"},{"key":"10.1016\/j.contraception.2025.111209_bib33","article-title":"Safety and effectiveness of contraception among women with chronic kidney disease: a systematic review","volume":"5","author":"Kortsmit","year":"2025","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.111209_bib34","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.contraception.2014.11.006","article-title":"Rationale and enrollment results for a partially randomized patient preference trial to compare continuation rates of short-acting and long-acting reversible contraception","volume":"91","author":"Hubacher","year":"2015","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.111209_bib35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/OGX.0000000000000272","article-title":"Pain management for gynecologic procedures in the office","volume":"71","author":"Ireland","year":"2016","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.contraception.2025.111209_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.contraception.2024.110385","article-title":"Factors associated with a negative patient acceptable symptom state (PASS) response with intrauterine device placement: a retrospective survey of HER salt lake participants","volume":"133","author":"Gero","year":"2024","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.111209_bib37","unstructured":"CDC. Supplementary Appendix. Grading of Recommendations Assessment, Development and Evaluation (GRADE) tables for recommendations reviewed, US\u00a0Selected Practice Recommendations for Contraceptive Use, 2024. 2024. Available from: \u3008https:\/\/stacks.cdc.gov\/view\/cdc\/156517\u3009 (accessed May 28, 2025)."},{"key":"10.1016\/j.contraception.2025.111209_bib38","doi-asserted-by":"crossref","first-page":"524.e1","DOI":"10.1016\/j.ajog.2024.05.038","article-title":"Mepivacaine instillation for pain reduction during intrauterine device placement in nulliparous women: a double-blinded randomized trial","volume":"231","author":"Envall","year":"2024","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2025.111209_bib39","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/01.AOG.0000435452.86108.59","article-title":"Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use","volume":"122","author":"Grunloh","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2025.111209_bib40","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.fertnstert.2016.02.036","article-title":"A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant","volume":"106","author":"Apter","year":"2016","journal-title":"Fertil Steril"},{"issue":"1","key":"10.1016\/j.contraception.2025.111209_bib41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/13625180801959931","article-title":"The effects of implanon on menstrual bleeding patterns","volume":"13","author":"Mansour","year":"2008","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2025.111209_bib42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.contraception.2022.04.011","article-title":"Values and preferences for contraception: a global systematic review","volume":"111","author":"Yeh","year":"2022","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.111209_bib43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.contraception.2021.05.018","article-title":"Contraceptive values and preferences of adolescents and young adults: a systematic review","volume":"111","author":"Ti","year":"2022","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.111209_bib44","unstructured":"Cohen M, Snyder EM, Curtis KM, Nguyen AT, Clark EA, Folger SG, et al. Management of bleeding irregularities with contraceptive implant use: a systematic review. Contraception. (under final review)."},{"key":"10.1016\/j.contraception.2025.111209_bib45","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/AOG.0000000000004659","article-title":"Patient-centered contraceptive counseling: ACOG committee statement number 1","volume":"139","author":"American College of Obstetricians and Gynecologists\u2019 Committee on Health Care for Underserved Women, Contraceptive Equity Expert Work Group, and Committee on Ethics","year":"2022","journal-title":"Obstet Gynecol"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782425004007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782425004007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T02:17:13Z","timestamp":1780712233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782425004007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":45,"alternative-id":["S0010782425004007"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2025.111209","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research gaps in evidence-based contraception guidance: US Medical Eligibility Criteria for Contraceptive Use, 2024, and US Selected Practice Recommendations for Contraceptive Use, 2024","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2025.111209","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111209"}}